 ROCKVILLE, Md., Oct. 1, 2021 PRNewswire -- Suprachoroidal delivery of RGX-314 well tolerated in 50 patients in Cohorts 1-3 with no drug-related serious adverse events Positive initial data from Cohort 1 at six months after one-time treatment of RGX-314 Treatment effect observed with stable visual acuity and retinal thickness Demonstrated meaningful reduction in anti-VEGF treatment burden Phase II trial expanded to include third dose level of RGX-314 1x1012 GCeye Company to host conference call and webcast on Friday, October 1 at 5:00 p.m. 